Regeneron Pharmaceuticals, Inc. (REGN) Net Profit Margin: 29.65%
Is Regeneron Pharmaceuticals, Inc.’s net profit margin high or low?
Regeneron Pharmaceuticals, Inc.'s net profit margin of 29.65% is 19% below its 5-year average of 36.64%, near the low end of its 5-year range (29.65%–50.25%).
As of Wednesday, June 17, 2026. 5.09% below its 12-month average of 31.24%.
REGN Net Profit Margin Chart
REGN Average Net Profit Margin Chart
REGN Current vs Average Net Profit Margin Chart
REGN Net Profit Margin Metrics
NET PROFIT MARGIN
29.65%
NET PROFIT MARGIN AVG TTM
31.24%
NET PROFIT MARGIN AVG 3Y
32.06%
NET PROFIT MARGIN AVG 5Y
36.64%
NET PROFIT MARGIN AVG 10Y
31.17%
NET PROFIT MARGIN AVG 15Y
30.70%
NET PROFIT MARGIN AVG 20Y
11.59%
CURRENT VS TTM AVG
-5.09%
CURRENT VS 3Y AVG
-7.53%
CURRENT VS 5Y AVG
-19.08%
CURRENT VS 10Y AVG
-4.88%
CURRENT VS 15Y AVG
-3.42%
CURRENT VS 20Y AVG
+155.75%
REGN Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. (REGN) | $63.33B | 29.65% | 31.24% | 32.06% | 36.64% |
| Boston Scientific Corporation (BSX)vs › | $66.81B | 17.24% | 12.73% | 10.54% | 8.34% |
| Cencora, Inc. (COR)vs › | $53.91B | 0.78% | 0.49% | 0.59% | 0.22% |
| Cardinal Health, Inc. (CAH)vs › | $53.10B | 0.62% | 0.54% | 0.18% | -0.22% |
| Becton, Dickinson and Company (BDX)vs › | $52.59B | 5.33% | 8.06% | 8.30% | 8.27% |
| Cigna Corporation (CI)vs › | $76.25B | 2.26% | 1.78% | 2.48% | 3.04% |
| IDEXX Laboratories, Inc. (IDXX)vs › | $45.20B | 24.63% | 23.70% | 22.66% | 22.55% |
| Humana Inc. (HUM)vs › | $43.72B | 0.82% | 0.97% | 1.82% | 2.53% |
| Elevance Health Inc. (ELV)vs › | $85.70B | 2.62% | 3.11% | 3.37% | 3.60% |
| HCA Healthcare, Inc. (HCA)vs › | $86.23B | 8.89% | 8.57% | 8.64% | 8.95% |
Margin Comparison
Operating Margin
24.3%
Net Profit Margin
29.6%
Regeneron Pharmaceuticals, Inc. Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Regeneron Pharmaceuticals, Inc. Net Profit Margin FAQ
- What is the net profit margin for Regeneron Pharmaceuticals, Inc. (REGN)?
- The net profit margin for REGN stock is 29.65%.
- Is Regeneron Pharmaceuticals, Inc.'s net profit margin high or low?
- Regeneron Pharmaceuticals, Inc.'s net profit margin of 29.65% is 19% below its 5-year average of 36.64%, near the low end of its 5-year range (29.65%–50.25%).
- What is the TTM average net profit margin for Regeneron Pharmaceuticals, Inc. (REGN)?
- The TTM average net profit margin for REGN stock is 31.24%.
- What is the 3Y average net profit margin for Regeneron Pharmaceuticals, Inc. (REGN)?
- The 3Y average net profit margin for REGN stock is 32.06%.
- What is the 5Y average net profit margin for Regeneron Pharmaceuticals, Inc. (REGN)?
- The 5Y average net profit margin for REGN stock is 36.64%.
- What is the 10Y average net profit margin for Regeneron Pharmaceuticals, Inc. (REGN)?
- The 10Y average net profit margin for REGN stock is 31.17%.
- What is the 15Y average net profit margin for Regeneron Pharmaceuticals, Inc. (REGN)?
- The 15Y average net profit margin for REGN stock is 30.70%.
- What is the 20Y average net profit margin for Regeneron Pharmaceuticals, Inc. (REGN)?
- The 20Y average net profit margin for REGN stock is 11.59%.
Regeneron Pharmaceuticals, Inc. Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2025-12-31 | 31.41% |
| 2024-12-31 | 31.07% |
| 2023-12-31 | 30.14% |
| 2022-12-31 | 35.64% |
| 2021-12-31 | 50.25% |
| 2020-12-31 | 41.35% |
| 2019-12-31 | 32.26% |
| 2018-12-31 | 36.42% |
| 2017-12-31 | 20.41% |
| 2016-12-31 | 18.42% |
| 2015-12-31 | 15.50% |
| 2014-12-31 | 12.34% |
| 2013-12-31 | 20.16% |
| 2012-12-31 | 54.43% |
| 2011-12-31 | -49.74% |
| 2010-12-31 | -22.76% |
| 2009-12-31 | -17.88% |
| 2008-12-31 | -34.69% |
| 2007-12-31 | -84.46% |
| 2006-12-31 | -161.30% |
| 2005-12-31 | -144.19% |
| 2004-12-31 | 23.96% |
| 2003-12-31 | -186.89% |
| 2002-12-31 | -565.66% |
| 2001-12-31 | -346.70% |
| 2000-12-31 | -39.16% |
| 1999-12-31 | -66.96% |
| 1998-12-31 | -22.51% |
| 1997-12-31 | -35.05% |
| 1996-12-31 | -134.44% |
Related Metrics
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Leonard S. Schleifer